Voloridge Investment Management, LLC Protagonist Therapeutics, Inc Transaction History

Voloridge Investment Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.02 - $29.36 $8.1 Million - $13.2 Million	-449,735 Reduced 96.65%	15,588 $430,000
Q1 2023 May 15, 2023	BUY	$10.78 - $25.38 $3.21 Million - $7.56 Million	297,954 Added 178.02%	465,323 $10.7 Million
Q4 2022 Feb 14, 2023	SELL	$7.36 - $11.17 $1.91 Million - $2.89 Million	-259,024 Reduced 60.75%	167,369 $1.83 Million
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $1.34 Million - $1.99 Million	-170,094 Reduced 28.52%	426,393 $3.59 Million
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $3.67 Million - $13.3 Million	519,886 Added 678.69%	596,487 $4.72 Million
Q1 2022 May 16, 2022	SELL	$23.34 - $36.08 $2.5 Million - $3.86 Million	-107,047 Reduced 58.29%	76,601 $1.81 Million
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $6.46 Million - $13.6 Million	-366,435 Reduced 66.61%	183,648 $6.28 Million
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $7.04 Million - $27 Million	543,579 Added 8357.61%	550,083 $9.75 Million
Q2 2021 Aug 16, 2021	BUY	$25.57 - $44.88 $166,307 - $291,899	6,504 New	6,504 $292,000

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Voloridge Investment Management, LLC with notifications on news.